Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Thomson Reuters Corp (TRI) Price & Performance

IDEXX Laboratories, Inc.Trade
Thomson Reuters CorpTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Thomson Reuters Corp — how do they compare? IDEXX Laboratories, Inc. trades at $520.09 (market cap $40.43B), while Thomson Reuters Corp trades at $101.92 (market cap $43.89B). The key difference: IDEXX Laboratories, Inc. and Thomson Reuters Corp are close in size by market cap, and Thomson Reuters Corp pays a 2.58% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Thomson Reuters Corp for 63 Days on average.

IDXXTRI
Market Cap
$40.43B$43.89B
Volume
692,1641,648,199
Sector
HealthIndustrials
52-Week High
$766.68$163.45
52-Week Low
$504.70$76.55
Typical Hold Time
46 Days63 Days
Enterprise Value
$41.32B$46.51B
Dividend Yield
—2.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.

The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.

Thomson Reuters Corp

Thomson Reuters (TRI) trades at $101.52, up 2.26% today, with bullish technical signals and strong analyst support. The company shows solid fundamentals with 10% organic growth in core businesses and a 21.22% net income margin. Recent strategic moves include divesting its printing unit and launching a proprietary AI model, positioning TRI for tech-focused growth. Cash flow trends show operational strength despite recent negative net cash flow due to strategic investments.

TRI presents a compelling investment case with analyst consensus target of $133.25 (31% upside), supported by recurring revenue growth and AI expansion. Risks include cybersecurity incidents and execution challenges in tech transformation. The stock's current valuation at 26.75 P/E appears reasonable given growth prospects, making it attractive for long-term investors seeking exposure to content and technology services.

Returns comparison

Trailing returns across standard periods

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →

About Thomson Reuters Corp

Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.

Read more on TRI →